Syros Pharmaceuticals Inc


Prices are adjusted according to historical splits.

Syros Pharmaceuticals Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$55.62 million
Book Value:
Revenue TTM:
$14.88 million
Operating Margin TTM:
Gross Profit TTM:
$14.88 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Syros Pharmaceuticals Inc had its IPO on 2016-06-30 under the ticker symbol SYRS.

The company operates in the Healthcare sector and Biotechnology industry. Syros Pharmaceuticals Inc has a staff strength of 117 employees.

Stock update

Shares of Syros Pharmaceuticals Inc opened at $2.8 at the start of the last trading session i.e. 2023-03-24.

The stocks traded within a range of $2.72 - $2.81, and closed at $2.74.

This is a -2.49% slip from the previous day's closing price.

A total volume of 46,872 shares were traded at the close of the day’s session.

In the last one week, shares of Syros Pharmaceuticals Inc have slipped by -8.05%.

Syros Pharmaceuticals Inc's Key Ratios

Syros Pharmaceuticals Inc has a market cap of $55.62 million, indicating a price to book ratio of 0.5794 and a price to sales ratio of 2.9904.

In the last 12-months Syros Pharmaceuticals Inc’s revenue was $14.88 million with a gross profit of $14.88 million and an EBITDA of $-132906000. The EBITDA ratio measures Syros Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Syros Pharmaceuticals Inc’s operating margin was -913.13% while its return on assets stood at -39.74% with a return of equity of -88.9%.

In Q4, Syros Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 31.7%.

Syros Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-7.46 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Syros Pharmaceuticals Inc’s profitability.

Syros Pharmaceuticals Inc stock is trading at a EV to sales ratio of 2.5783 and a EV to EBITDA ratio of 0.9901. Its price to sales ratio in the trailing 12-months stood at 2.9904.

Syros Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$244.49 million
Total Liabilities
$30.78 million
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Syros Pharmaceuticals Inc ended 2023 with $244.49 million in total assets and $0 in total liabilities. Its intangible assets were valued at $244.49 million while shareholder equity stood at $127.74 million.

Syros Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $30.78 million in other current liabilities, 20000.00 in common stock, $-558233000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $167.47 million and cash and short-term investments were $202.30 million. The company’s total short-term debt was $2,071,000 while long-term debt stood at $40.65 million.

Syros Pharmaceuticals Inc’s total current assets stands at $211.39 million while long-term investments were $0.00 and short-term investments were $34.84 million. Its net receivables were $1.69 million compared to accounts payable of $6.41 million and inventory worth $0.

In 2023, Syros Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $674000.

Comparatively, Syros Pharmaceuticals Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Syros Pharmaceuticals Inc stock is currently trading at $2.74 per share. It touched a 52-week high of $14.3 and a 52-week low of $14.3. Analysts tracking the stock have a 12-month average target price of $33.

Its 50-day moving average was $4.01 and 200-day moving average was $5.9 The short ratio stood at 4.11 indicating a short percent outstanding of 0%.

Around 155.7% of the company’s stock are held by insiders while 5219.5% are held by institutions.

Frequently Asked Questions About Syros Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Syros Pharmaceuticals Inc is SYRS

The IPO of Syros Pharmaceuticals Inc took place on 2016-06-30

Similar Industry Stocks (Biotechnology)

Last Price
BioCardia Inc (BCDAW)
Aroundtown SA (AANNF)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price
Imara Inc (IMRA)


Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company’s lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.


35 CambridgePark Drive, Cambridge, MA, United States, 02140